<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sophie Quoilin</style></author><author><style face="normal" font="default" size="100%">Veronik Hutse</style></author><author><style face="normal" font="default" size="100%">Vandenberghe, Hans</style></author><author><style face="normal" font="default" size="100%">Claeys, Françoise</style></author><author><style face="normal" font="default" size="100%">Verhaegen, Els</style></author><author><style face="normal" font="default" size="100%">De Cock, Liesbet</style></author><author><style face="normal" font="default" size="100%">Van Loock, Frank</style></author><author><style face="normal" font="default" size="100%">Top, Geert</style></author><author><style face="normal" font="default" size="100%">Van Damme, Pierre</style></author><author><style face="normal" font="default" size="100%">Vranckx, Robert</style></author><author><style face="normal" font="default" size="100%">Herman Van Oyen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Epidemiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Eur. J. Epidemiol.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADOLESCENT</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Child</style></keyword><keyword><style  face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">cross-sectional studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis A</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis A Antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B Surface Antigens</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C Antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Population Surveillance</style></keyword><keyword><style  face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">Saliva</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">195-202</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Ten years after the first seroprevalence study performed in Flanders, the aim of this cross sectional study was to follow the evolution of hepatitis A, B and C prevalence. The prevalence of hepatitis A antibodies, hepatitis B surface antigen and hepatitis C antibodies was measured in oral fluid samples collected by postal survey. Using the National Population Register, an incremental sampling plan was developed to obtain a representative sampling of the general population. A total of 24,000 persons were selected and 6,000 persons among them contacted in a first wave. With 1834 participants a response rate of 30.6% was achieved. The prevalence was weighted for age and was 20.2% (95% CI 19.43-21.08) for hepatitis A, 0.66% (95% CI 0.51-0.84) for hepatitis B surface antigen and 0.12% (95% CI 0.09-0.39) for hepatitis C. The prevalence of hepatitis A and C in the Flemish population is lower in 2003 compared with the results of the study performed in 1993. The difference may be due to a real decrease of the diseases but also to differences in the methodology. The prevalence of hepatitis B surface antigen remains stable. Considering the 30% response rate and the high quality of the self-collected samples as reflect of a good participation of the general population, saliva test for prevalence study is a good epidemiological monitoring tool.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/17356926?dopt=Abstract</style></custom1></record></records></xml>